Cargando…

Rapid resolution of cytokine release syndrome and favorable clinical course of severe COVID-19 in a kidney transplant recipient treated with tocilizumab

Detalles Bibliográficos
Autores principales:	Gautier-Vargas, Gabriela, Baldacini, Clement, Benotmane, Ilies, Keller, Nicolas, Perrin, Peggy, Moulin, Bruno, Caillard, Sophie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	International Society of Nephrology. Published by Elsevier Inc. 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7272169/ https://www.ncbi.nlm.nih.gov/pubmed/32505467 http://dx.doi.org/10.1016/j.kint.2020.05.022

Ejemplares similares

COVID-19 in a kidney transplant recipient treated with eculizumab for atypical hemolytic uremic syndrome: a case report
por: Cognard, Noëlle, et al.
Publicado: (2021)

Persistence of SARS-CoV-2 antibodies in kidney transplant recipients
por: Benotmane, Ilies, et al.
Publicado: (2021)

Weak anti–SARS-CoV-2 antibody response after the first injection of an mRNA COVID-19 vaccine in kidney transplant recipients
por: Benotmane, Ilies, et al.
Publicado: (2021)

Low immunization rates among kidney transplant recipients who received 2 doses of the mRNA-1273 SARS-CoV-2 vaccine
por: Benotmane, Ilies, et al.
Publicado: (2021)

Prediction of Vaccine Response and Development of a Personalized Anti-SARS-CoV-2 Vaccination Strategy in Kidney Transplant Recipients: Results from a Large Single-Center Study
por: Benotmane, Ilies, et al.
Publicado: (2022)

Prédiction de la sévérité de la COVID-19 par les biomarqueurs du syndrome de relargage cytokinique au sein d’une population de transplantés rénaux
por: Benotmane, I., et al.
Publicado: (2020)

A rapid decline in the anti–receptor-binding domain of the SARS-CoV-2 spike protein IgG titer in kidney transplant recipients after tixagevimab–cilgavimab administration
por: Benotmane, Ilies, et al.
Publicado: (2022)

Molecular evolution of the SARS-CoV-2 omicron BA.2 variant in kidney transplant recipients with prolonged viral shedding
por: Caillard, Sophie, et al.
Publicado: (2023)

Impaired P2Y12 inhibition by clopidogrel in kidney transplant recipients: results from a cohort study
por: Muller, Clotilde, et al.
Publicado: (2016)

Pre-exposure prophylaxis with 300 mg Evusheld elicits limited neutralizing activity against the Omicron variant
por: Benotmane, Ilies, et al.
Publicado: (2022)

Complications neurologiques du COVID-19 chez les patients atteints de maladie rénale
por: Perrin, P., et al.
Publicado: (2020)

A fourth dose of the mRNA-1273 SARS-CoV-2 vaccine improves serum neutralization against the Delta variant in kidney transplant recipients
por: Benotmane, Ilies, et al.
Publicado: (2022)

Avascular osteonecrosis in kidney transplant recipients: Risk factors in a recent cohort study and evaluation of the role of secondary hyperparathyroidism
por: Felten, Renaud, et al.
Publicado: (2019)

Occurrence of De novo Donor-Specific Antibodies After COVID-19 in Kidney Transplant Recipients Is Low Despite Immunosuppression Modulation
por: Masset, Christophe, et al.
Publicado: (2022)

A fourth SARS-CoV-2 mRNA vaccine in strictly seronegative kidney transplant recipients
por: Masset, Christophe, et al.
Publicado: (2022)

Gross hematuria following SARS-CoV-2 vaccination in patients with IgA nephropathy
por: Perrin, Peggy, et al.
Publicado: (2021)

Infection or a third dose of mRNA vaccine elicits neutralizing antibody responses against SARS-CoV-2 in kidney transplant recipients
por: Charmetant, Xavier, et al.
Publicado: (2022)

Favorable Outcome of COVID-19 Pneumonia in a Kidney Transplant Recipient Treated with Tocilizumab
por: Guella, Adnane, et al.
Publicado: (2020)

Development and validation of multivariable prediction models of serological response to SARS-CoV-2 vaccination in kidney transplant recipients
por: Osmanodja, Bilgin, et al.
Publicado: (2022)

The effect of tocilizumab on cytokine release syndrome in COVID-19 patients
por: de Cáceres, Carmen, et al.
Publicado: (2020)

Utilizing tocilizumab for the treatment of cytokine release syndrome in COVID-19
por: Hassoun, Ali, et al.
Publicado: (2020)

Granulomatous Inflammation and Hypercalcemia in Patients With Severe Systemic Oxalosis
por: Perrin, Peggy, et al.
Publicado: (2021)

In Reply to “Letter Regarding ‘Granulomatous Inflammation and Hypercalcemia in Patients With Severe Systemic Oxalosis’”
por: Perrin, Peggy, et al.
Publicado: (2022)

Effectiveness of Tocilizumab in a COVID-19 Patient with Cytokine Release Syndrome
por: Uslu, Sadettin
Publicado: (2020)

Tocilizumab in Severe COVID-19 Pneumonia and Concomitant Cytokine Release Syndrome
por: van Kraaij, Tom DA, et al.
Publicado: (2020)

Tocilizumab Use among Patients Who Developed Pulmonary Embolism in the Course of Cytokine Release Storm and COVID-19 Pneumonia—A Retrospective Study
por: Chober, Daniel, et al.
Publicado: (2022)

Early Exposure of Kidney Transplant Recipients with Chronic Antibody-Mediated Rejection to Tocilizumab—A Preliminary Study
por: Arrivé, Capucine, et al.
Publicado: (2023)

Eculizumab for Thrombotic Microangiopathy Associated with Antibody-Mediated Rejection after ABO-Incompatible Kidney Transplantation
por: Lanfranco, Luca, et al.
Publicado: (2017)

Combining predictive markers for severe COVID-19: Torquetenovirus DNA load and SARS-CoV-2 RNAemia
por: Solis, Morgane, et al.
Publicado: (2022)

Evaluation of infliximab/tocilizumab versus tocilizumab among COVID-19 patients with cytokine storm syndrome
por: Sarhan, Neven Mohamed, et al.
Publicado: (2023)

COVID-19 vaccination in kidney transplant recipients
por: Caillard, Sophie, et al.
Publicado: (2021)

Tocilizumab Use in COVID-19 Cytokine-release Syndrome: Retrospective Study of Two Centers
por: Nasa, Prashant, et al.
Publicado: (2020)

Tocilizumab-induced Leukoencephalopathy with a Reversible Clinical Course
por: Sasaki, Ryo, et al.
Publicado: (2020)

Can tocilizumab calm the cytokine storm of COVID-19?
por: Schulert, Grant S
Publicado: (2020)

Delayed COVID‐19‐induced cytokine storm after root canal therapy with favorable response to plasmapheresis, tocilizumab, and methylprednisolone pulses therapy: A case report
por: Aghaeimeybodi, Fatemeh, et al.
Publicado: (2022)

Is the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) present intraperitoneally in patients with coronavirus disease 2019 (COVID-19) infection undergoing emergency operations?
por: Seeliger, Barbara, et al.
Publicado: (2020)

Favorable changes of CT findings in a patient with COVID-19 pneumonia after treatment with tocilizumab
por: Cellina, M., et al.
Publicado: (2020)

Spotlight on Tocilizumab in the Treatment of CAR-T-Cell-Induced Cytokine Release Syndrome: Clinical Evidence to Date
por: Si, Stephanie, et al.
Publicado: (2020)

Tocilizumab in a child with acute lymphoblastic leukaemia and COVID-19-related cytokine release syndrome()
por: Velasco Puyó, Pablo, et al.
Publicado: (2020)

Use of Tocilizumab for COVID-19-Induced Cytokine Release Syndrome: A Cautionary Case Report
por: Radbel, Jared, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_orp2ofu26d1esv2l13aa6d37gc